New China MDR Export Certificate Rules Take Effect May 1, 2026

China’s National Medical Products Administration (NMPA) has implemented revised Regulations on the Management of Export Sales Certificates for Medical Devices effective May 1, 2026. The update allows actual manufacturers — including those producing unregistered or unfiled devices for export only, such as ODM hemodiafiltration machines and vacuum autoclaves — to directly apply for an Export Sales Certificate (II), provided they meet Good Manufacturing Practice (GMP) requirements. This change is particularly relevant for medical device exporters, contract manufacturers, and international procurement entities operating in regulated global markets.

Event Overview

The NMPA’s revised Regulations on the Management of Export Sales Certificates for Medical Devices entered into force on May 1, 2026. As officially published, the regulation explicitly permits the actual manufacturing entity — rather than a China-based registrant or marketing authorization holder — to apply for an Export Sales Certificate (II) for devices not registered or filed in China. Eligibility requires compliance with China’s GMP standards for medical devices. No additional implementation guidance or transitional provisions beyond the effective date have been publicly released.

Industries Affected

Contract and ODM Manufacturing Enterprises

These enterprises are directly impacted because the rule now formally recognizes their role as certificate applicants for export-only products. Previously, such applications often required coordination with a China-based registrant — a bottleneck for pure-export ODM arrangements. The change reduces administrative dependency and clarifies eligibility criteria tied to GMP compliance, not registration status.

Export-Only Trading Companies

Trading companies without domestic registration portfolios may benefit indirectly: streamlined access to valid Export Sales Certificates (II) from their manufacturing partners improves documentation reliability for overseas customs and regulatory submissions. However, they remain responsible for verifying that their suppliers hold current GMP certification and maintain accurate production records supporting the certificate application.

International Procurement & Distributor Entities

Buyers sourcing devices like hemodiafiltration systems or sterilization equipment from Chinese factories must now assess whether their suppliers’ Export Sales Certificates (II) were issued under this new framework. Certificates issued post–May 1, 2026, do not imply product registration in China — a distinction critical for market entry assessments in jurisdictions requiring evidence of home-country regulatory standing.

Key Considerations and Recommended Actions

Monitor official NMPA guidance on GMP verification procedures

While the regulation states GMP compliance is mandatory, it does not specify how conformity will be assessed during certificate review (e.g., via on-site inspection, self-declaration, or third-party audit reports). Enterprises should track upcoming NMPA notices or provincial bureau announcements clarifying evidentiary expectations.

Verify certificate type and issuance basis for all new orders

Export Sales Certificates (II) issued under the revised rules differ substantively from (I)-type certificates (which require domestic registration). Buyers and logistics providers should confirm the certificate type and its stated legal basis — especially when submitting documentation to regulators in ASEAN, Latin America, or the Middle East, where misclassification may delay clearance.

Distinguish policy intent from operational readiness

Analysis shows the regulation lowers a formal barrier but does not eliminate documentation or quality system requirements. Actual implementation depends on provincial NMPA offices’ capacity to process applications and verify GMP adherence. Enterprises should avoid assuming immediate processing efficiency and instead treat early applications as pilot cases requiring close follow-up.

Update internal SOPs and supplier questionnaires

Procurement and regulatory affairs teams should revise supplier qualification checklists to include explicit confirmation of GMP certification scope (covering the exported device), validity period, and alignment with the new certificate application pathway. Contracts with Chinese manufacturers should reference compliance with the May 2026 regulation where applicable.

Editorial Observation / Industry Perspective

Observably, this revision reflects a pragmatic adjustment to China’s export control framework — prioritizing traceability and quality assurance over domestic market authorization as the sole condition for export documentation. It is better understood as a procedural enabler than a de facto regulatory relaxation: the GMP requirement remains binding, and non-compliance risks certificate revocation or enforcement action. From an industry perspective, the rule signals increasing recognition of China’s role as a global contract manufacturing hub — yet its real-world impact hinges on consistent provincial-level execution and transparency around verification methods. Continued monitoring of certificate issuance patterns and related FAQs from NMPA will be essential over the coming months.

Conclusion: The revised regulation simplifies one layer of export documentation for unregistered devices but shifts responsibility toward robust GMP maintenance and inter-company documentation alignment. It is neither a broad deregulatory shift nor a standalone compliance solution — rather, it represents a targeted recalibration of administrative accountability in China’s medical device export ecosystem. Current interpretation should focus on operational preparedness, not regulatory assumption.

Source: National Medical Products Administration (NMPA) of the People’s Republic of China — Regulations on the Management of Export Sales Certificates for Medical Devices, effective May 1, 2026.
Note: Implementation details, including provincial acceptance criteria and GMP verification protocols, remain subject to ongoing observation and are not yet publicly standardized.